St. Jude Medical Inc. (NYSE:STJ) received Australian regulatory approval to begin selling a deep-brain-stimulation device for people suffering from Parkinson’s disease.
St. Jude said its Brio device is the smallest, longest-lasting rechargeable deep-brain stimulation system on the market. The device is about the size of a wristwatch, weighing 29 grams and featuring a 10-year battery life, according to a press release.
Parkinson’s is a degenerative brain disease caused by damage to nerve cells in the brain. It often results in impaired movement and speech. Deep-brain stimulation delivers electrical pulses that block “abnormal” signals from the brain that cause tremors and other symptoms associated with the ailment.
The Australian approval gives St. Jude another market for the device and an opportunity to increase sales for its neuromodulation division. That division posted a bigger fourth-quarter sales increase, 21 percent to $94 million, than any segment at St. Jude.
The Brio system was cleared for sale in the European Union last year, according to the press release. It hasn’t received regulatory approval in the U.S.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.